Controlled trial comparing olsalazine and sulphasalazine for maintenance treatment of ulcerative colitis.
Olsalazine and sulphasalazine were compared in a double-blind, double-dummy trial in the prevention of relapse of ulcerative colitis over 6 months. The majority were taking sulphasalazine. They were randomized to receive either olsalazine, 500 mg b.d., or sulphasalazine, 1 g b.d. Of 82 patients, 16 relapsed on olsalazine compared with 10 of 82 on sulphasalazine. This difference was not statistically significant (p = 0.16). Twenty-one patients reported adverse events in the olsalazine group, of whom 16 were withdrawn, while 20 patients reported adverse events in the sulphasalazine group, with 9 of them being withdrawn. The differences were not statistically significant. No major haematological or biochemical abnormalities occurred. Thus, olsalazine is similar to sulphasalazine for the prevention of relapse of ulcerative colitis.
Jewell
D P
DP
Gastroenterology Unit, Radcliffe Infirmary, Oxford, U.K.
Ireland
A
A
D000636:Aminosalicylic Acids / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003093:Colitis, Ulcerative / Q000188:drug therapy*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011897:Random Allocation; D012008:Recurrence; D012460:Sulfasalazine / Q000627:therapeutic use*; D013997:Time Factors
D000636:Aminosalicylic Acids; D012460:Sulfasalazine; C032587:olsalazine